
|Videos|October 26, 2017
Dr. Brammer on Brentuximab Vedotin for Patients With T-Cell Lymphoma
Author(s)Jonathan E. Brammer, MD
Jonathan E. Brammer, MD, assistant professor of hematology, Ohio State University Comprehensive Cancer Center, discusses brentuximab vedotin (Adcetris) for patients with T-cell lymphoma.
Advertisement
Jonathan E. Brammer, MD, assistant professor of hematology, Ohio State University Comprehensive Cancer Center, discusses brentuximab vedotin (Adcetris) for patients with T-cell lymphoma.
An issue in the landscape that is currently being explored is whether brentuximab vedotin is effective in the frontline setting as has been shown in Hodgkin lymphoma. Preliminary studies have shown that brentuximab vedotin does seem to have some efficacy in other CD30-positive T-cell lymphomas.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
2
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
3
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
4
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
5



































